Security
Dianthus Therapeutics, Inc. Common Stock · DNTH
DNTHNASDAQCommon stockCurrentCIK 1690585Updated Nov 2, 2026
Name history
Magenta Therapeutics, Inc. · through Sep 8, 2023
DNTH price & chart
Loading TradingView…
NASDAQ:DNTH on TradingView ↗About the company
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
In the news
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting ↗
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 577,445,000Source | 354,248,000Source | 1,213,271,000Source | 326,076,000Source | 368,959,000Source | 1,246,884,000Source | 348,580,000Source | 382,462,000Source | 530,922,000Source | 374,008,000Source | 179,405,000Source | 146,645,000Source |
| Property, Plant and Equipment, NetUSD | 185,000Source | 189,000Source | 418,000Source | 207,000Source | 189,000Source | 274,000Source | 191,000Source | 195,000Source | 296,000Source | 194,000Source | 185,000Source | 6,095,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 55,984,000Source | 33,671,000Source | 110,549,000Source | 13,237,000Source | 314,169,000Source | 627,667,000Source | 10,116,000Source | 329,724,000Source | 51,087,000Source | 22,792,000Source | 132,325,000Source | 57,626,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 5,000,000Source | 1,390,000Source | 106,000Source | 39,000Source | 840,000Source | 1,230,000Source | 1,000,000Source | 435,000Source | 52,000Source | 807,000Source | 294,000Source | — |
| Assets, CurrentUSD | 413,825,000Source | 287,489,000Source | 897,537,000Source | 263,605,000Source | 365,687,000Source | 1,119,911,000Source | 270,999,000Source | 380,926,000Source | 409,438,000Source | 280,904,000Source | 177,451,000Source | 115,602,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,212,000Source | 3,683,000Source | 10,618,000Source | 6,177,000Source | 3,305,000Source | 7,422,000Source | 6,769,000Source | 3,014,000Source | 5,091,000Source | 4,856,000Source | 3,255,000Source | 3,561,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,306,000Source | 352,000Source | 1,223,000Source | 1,378,000Source | 442,000Source | 1,293,000Source | 1,447,000Source | 530,000Source | 1,337,000Source | 1,553,000Source | 615,000Source | 23,168,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 30,991,000Source | 16,350,000Source | 41,246,000Source | 22,997,000Source | 10,741,000Source | 45,570,000Source | 19,974,000Source | 9,775,000Source | 37,521,000Source | 21,531,000Source | 10,535,000Source | 40,687,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 43,000Source | 29,000Source | 55,000Source | 32,000Source | 29,000Source | 54,000Source | 32,000Source | 29,000Source | 43,000Source | 31,000Source | 15,000Source | 61,000Source |
| Retained Earnings (Accumulated Deficit)USD | -272,297,000Source | -145,952,000Source | -427,778,000Source | -235,532,000Source | -120,778,000Source | -377,563,000Source | -203,903,000Source | -103,171,000Source | -336,729,000Source | -174,392,000Source | -89,423,000Source | -402,029,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 163,000Source | 681,000Source | -2,128,000Source | 98,000Source | -37,000Source | -575,000Source | 270,000Source | -27,000Source | 489,000Source | 106,000Source | 47,000Source | -181,000Source |
| Stockholders' Equity Attributable to ParentUSD | 546,454,000Source | 337,898,000Source | 1,172,025,000Source | 303,079,000Source | 358,218,000Source | 1,201,314,000Source | 328,606,000Source | 372,687,000Source | 493,401,000Source | 352,477,000Source | 168,870,000Source | 105,958,000Source |
| Additional Paid in Capital, Common StockUSD | 818,545,000Source | 483,140,000Source | 1,601,876,000Source | 538,481,000Source | 479,004,000Source | 1,579,398,000Source | 532,207,000Source | 475,856,000Source | 829,598,000Source | 526,732,000Source | 258,231,000Source | 508,107,000Source |
| Liabilities and EquityUSD | 577,445,000Source | 354,248,000Source | 1,213,271,000Source | 326,076,000Source | 368,959,000Source | 1,246,884,000Source | 348,580,000Source | 382,462,000Source | 530,922,000Source | 374,008,000Source | 179,405,000Source | 146,645,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 23,855,000Source | 15,710,000Source | 34,389,000Source | 20,093,000Source | 10,029,000Source | 38,283,000Source | 16,953,000Source | 8,959,000Source | 30,732,000Source | 18,452,000Source | 9,631,000Source | 14,549,000Source |
| Operating Lease, Liability, CurrentUSD | 217,000Source | 311,000Source | 374,000Source | 211,000Source | 377,000Source | 399,000Source | 226,000Source | 400,000Source | 367,000Source | 320,000Source | 417,000Source | 3,824,000Source |
| Accounts Payable, CurrentUSD | 6,705,000Source | 7,572,000Source | 6,390,000Source | 5,404,000Source | 3,695,000Source | 5,274,000Source | 8,269,000Source | 2,612,000Source | 9,725,000Source | 4,579,000Source | 2,610,000Source | 2,454,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,068,000Source | 0Source | 913,000Source | 1,119,000Source | 30,000Source | 965,000Source | 1,170,000Source | 97,000Source | 1,019,000Source | 1,171,000Source | 168,000Source | 26,138,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 15,979,000Source | 7,727,000Source | 26,101,000Source | 13,999,000Source | 5,857,000Source | 31,125,000Source | 7,979,000Source | 5,847,000Source | 19,452,000Source | 13,074,000Source | 6,504,000Source | 8,271,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 54,994,000Source | — | 107,611,000Source | 11,951,000Source | — | 617,109,000Source | 9,254,000Source | — | 50,247,000Source | 21,946,000Source | — | — |
| Deferred Revenue, CurrentUSD | 954,000Source | 100,000Source | 1,524,000Source | 479,000Source | 100,000Source | 1,485,000Source | 479,000Source | 100,000Source | 1,188,000Source | 479,000Source | 100,000Source | — |
| Deferred Revenue, NoncurrentUSD | 6,068,000Source | 640,000Source | 5,944,000Source | 1,785,000Source | 682,000Source | 6,322,000Source | 1,851,000Source | 719,000Source | 5,770,000Source | 1,908,000Source | 736,000Source | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 480,000Source | 227,000Source | 13,309,000Source | 7,220,000Source |
| Short-term InvestmentsUSD | 346,629,000Source | 247,452,000Source | 776,264,000Source | 244,152,000Source | 46,538,000Source | 483,592,000Source | 253,114,000Source | 47,312,000Source | 353,208,000Source | 252,449,000Source | 41,393,000Source | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -40,834,000Source | -29,511,000Source | -162,337,000Source | -84,969,000Source | -43,555,000Source | -76,462,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | — | — | — | — | 1,925,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 10,602,000Source | 5,315,000Source | 22,793,000Source | 12,894,000Source | 2,900,000Source | 7,021,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 1,178,000Source | 1,000,000Source | 52,000Source | — | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | — | — | — | — | — | -801,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -28,856,000Source | -27,630,000Source | -129,060,000Source | -78,180,000Source | -36,861,000Source | -67,090,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -133,973,000Source | 14,794,000Source | -122,833,000Source | -286,812,000Source | 20,253,000Source | -9,812,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | 314,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 739,410,000Source | 161,000Source | 280,125,000Source | 255,623,000Source | 133,574,000Source | 2,878,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 576,581,000Source | -12,675,000Source | 28,232,000Source | -109,369,000Source | 116,966,000Source | -74,024,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 56,151,000Source | 33,900,000Source | 110,717,000Source | 13,468,000Source | 627,835,000Source | 10,347,000Source | 51,254,000Source | 23,022,000Source | 132,391,000Source | 59,406,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 5,794,000Source | 3,840,000Source | 11,898,000Source | 5,706,000Source | 10,602,000Source | 5,315,000Source | 22,793,000Source | 12,894,000Source | 2,900,000Source | 7,021,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 54,994,000Source | — | 107,611,000Source | 11,951,000Source | 617,109,000Source | 9,254,000Source | 50,247,000Source | 21,946,000Source | — | — |
| DepreciationUSD | — | — | 27,000Source | 25,000Source | 37,000Source | 30,000Source | 32,000Source | 27,000Source | 111,000Source | 96,000Source | 67,000Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -2,000Source | -48,000Source | -10,000Source | -30,000Source | -15,000Source | -22,000Source | -57,000Source | -64,000Source | -85,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| General and Administrative ExpenseUSD | — | — | 8,195,000Source | 6,528,000Source | 13,557,000Source | 8,869,000Source | 12,468,000Source | 7,337,000Source | 34,331,000Source | 24,994,000Source | 18,159,000Source | 25,761,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | — | — | 1,347,000Source | 2,104,000Source | 5,888,000Source | 2,305,000Source | 5,047,000Source | 1,892,000Source | 9,956,000Source | 11,347,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -36,765,000Source | -25,174,000Source | -50,215,000Source | -31,629,000Source | -40,834,000Source | -29,511,000Source | -162,337,000Source | -84,969,000Source | -43,555,000Source | -76,462,000Source |
| Nonoperating Income (Expense)USD | — | — | 3,523,000Source | 4,726,000Source | 11,267,000Source | 3,298,000Source | 5,699,000Source | 3,666,000Source | 15,596,000Source | 16,895,000Source | 4,619,000Source | — |
| Operating ExpensesUSD | — | — | 40,684,000Source | 32,072,000Source | 62,243,000Source | 35,120,000Source | 46,996,000Source | 34,340,000Source | 179,969,000Source | 108,099,000Source | 51,000,000Source | 80,902,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -360,000Source | 22,000Source | -370,000Source | -107,000Source | -249,000Source | -98,000Source | -974,000Source | -554,000Source | -60,000Source | — |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 238,588,000Source | 67,324,000Source | 435,013,000Source | 413,707,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 120,000Source | 129,000Source | 317,000Source | 39,200,000Source | — | 2,904,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 4,277,000Source | 31,000Source | 7,903,000Source | 1,090,000Source | 5,000Source | 0Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 396,000Source | 2,172,000Source | — | 193,000Source | — | 1,163,000Source | 2,036,000Source | 6,235,000Source | — | — |
| Operating Income (Loss)USD | — | — | -40,288,000Source | -29,900,000Source | -61,482,000Source | -34,927,000Source | -46,533,000Source | -33,177,000Source | -177,933,000Source | -101,864,000Source | -48,174,000Source | -80,902,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -360,000Source | 22,000Source | -370,000Source | -107,000Source | -249,000Source | -98,000Source | -974,000Source | -554,000Source | -60,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -36,765,000Source | -25,174,000Source | -50,215,000Source | -31,629,000Source | -40,834,000Source | -29,511,000Source | -162,337,000Source | -84,969,000Source | -43,555,000Source | -76,462,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.97Source | -0.74Source | -0.9Source | -0.88Source | -0.85Source | -0.82Source | -4.2Source | -2.55Source | -8.45Source | -1.29Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.97Source | -0.74Source | -0.9Source | -0.88Source | -0.85Source | -0.82Source | -4.2Source | -2.55Source | -8.45Source | -1.29Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 37,794,088Source | 34,236,728Source | 56,029,124Source | 35,822,308Source | 48,032,742Source | 35,790,700Source | 38,617,580Source | 33,313,849Source | 5,153,423Source | 59,372,357Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 37,794,088Source | 34,236,728Source | 56,029,124Source | 35,822,308Source | 48,032,742Source | 35,790,700Source | 38,617,580Source | 33,313,849Source | 5,153,423Source | 59,372,357Source |
| Additional Financial Items | ||||||||||||
| Common Stock, Dividends, Per Share, DeclaredUSD per share | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -2,000Source | -48,000Source | -10,000Source | -30,000Source | -15,000Source | -22,000Source | -57,000Source | -64,000Source | -85,000Source | — |
| General and Administrative ExpenseUSD | — | — | 8,195,000Source | 6,528,000Source | 13,557,000Source | 8,869,000Source | 12,468,000Source | 7,337,000Source | 34,331,000Source | 24,994,000Source | 18,159,000Source | 25,761,000Source |
| Interest and Other IncomeUSD | — | — | — | — | — | — | — | — | — | — | — | 4,440,000Source |
| Interest Income, OperatingUSD | — | — | — | — | 11,542,000Source | 3,403,000Source | 6,265,000Source | 3,791,000Source | 16,119,000Source | 17,365,000Source | — | — |
| Interest Income, OtherUSD | — | — | — | 4,445,000Source | — | — | — | — | — | 17,365,000Source | 4,764,000Source | — |
| Investment Income, InterestUSD | — | — | 1,347,000Source | 2,104,000Source | 5,888,000Source | 2,305,000Source | 5,047,000Source | 1,892,000Source | 9,956,000Source | 11,347,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 3,523,000Source | 4,726,000Source | 11,267,000Source | 3,298,000Source | 5,699,000Source | 3,666,000Source | 15,596,000Source | 16,895,000Source | 4,619,000Source | — |
| Operating ExpensesUSD | — | — | 40,684,000Source | 32,072,000Source | 62,243,000Source | 35,120,000Source | 46,996,000Source | 34,340,000Source | 179,969,000Source | 108,099,000Source | 51,000,000Source | 80,902,000Source |
| Research and Development ExpenseUSD | — | — | 32,489,000Source | 25,544,000Source | 48,686,000Source | 26,251,000Source | 34,528,000Source | 27,003,000Source | 145,638,000Source | 83,105,000Source | 32,841,000Source | 55,141,000Source |
Offerings
Registration 333-299012
Registration 333-294197
Registration 333-293014
Filing attachments
d184758dex49.htm · S-3ASR · 2026-09-18
Exhibit 4.9 DIANTHUS THERAPEUTICS, INC. Debt Securities Indenture Dated as of, 202 [ ], as Trustee CROSS-REFERENCE TABLE This Cross-Reference Table is not a part of the Indenture TIA Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (b) 7.08; 7.10; 12.02 311(a) 7.11 (b) 7.11 (c) …
Read attachment ↗dnth-ex99_1.htm · 8-K · 2026-08-04
EX-99.1 2 dnth-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q2 2026 FINANCIAL RESULTS Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN) Phase 3 EMERGE registrational trial of clasepruba…
Read attachment ↗dnth-ex99_1.htm · 8-K · 2026-06-12
EX-99.1 2 dnth-ex99_1.htm EX-99.1 Advancing a leading autoimmune-focused company June 2026 Exhibit 99.1 Forward-looking statements Certain statements in this presentation, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, express or implied statements regarding future plans and pr…
Read attachment ↗d12147715_ex99-1.htm · SCHEDULE 13G · 2026-05-15
EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the …
Read attachment ↗dnth-ex99_1.htm · 8-K · 2026-05-05
EX-99.1 2 dnth-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q1 2026 FINANCIAL RESULTS Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Claseprubart granted Orphan Drug Designation by FDA for Myasthenia Gravis Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W and 300mg/2mL…
Read attachment ↗dnth-ex99_1.htm · 8-K · 2026-03-26
EX-99.1 2 dnth-ex99_1.htm EX-99.1 Advancing a leading autoimmune-focused company March 2026 Exhibit 99.1 Forward-looking statements Certain statements in this presentation, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, express or implied statements regarding future plans and p…
Read attachment ↗